Commentary|Podcasts|November 8, 2024

Key Findings of the NIAGARA and HIMALAYA Trials

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

AstraZeneca's Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses:

Results of the NIAGARA trial in bladder cancer

The significance of the five-year overall survival data from the HIMALAYA trial, specifically the long-term efficacy of the STRIDE regimen for unresectable liver cancer
and much more!

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

October 26th, 2026

Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

November 2nd, 2026

Pharmaceutical Executive Daily: FDA Approves Voceryq

FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.

November 2nd, 2026

States Take Center Stage in the Drug Pricing Fight

PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.

October 30th, 2026

Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica

Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.

Dave Sunderhaft, Chief Operating Officer nPhase, Inc.

October 29th, 2026

Rebuilding Clinical Data Workflows for the AI Era

As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.

October 29th, 2026

How Preventative Medications May Impact the Lingering Impact of COVID-19

Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.

October 28th, 2026

Should There be More of a Focus on Developing Preventative Medications

Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.

Sam Anwar, Chief Technology Officer at eClinical Solutions

October 28th, 2026

The Next Biopharma Revolution: Quantum Computing

The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities

Trending on PharmExec

What is it Like to Go From Treating Patients Directly to Running a Company?

FDA Grants Accelerated Approval to INOVIO’s Voceryq for RRP, Reducing Surgical Burden

FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

States Take Center Stage in the Drug Pricing Fight

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion